Does Security Health Plan Cover Rogaine?

Why OTC Rogaine Falls Outside Most Insurance Formularies

Most health insurance plans, Security Health Plan included, build their pharmacy benefits around prescription-only medications. Rogaine (minoxidil topical solution and foam) switched from prescription to OTC status in 1996, and that switch removed it from the majority of commercial formularies nationwide.

The logic is straightforward. Insurance formularies are negotiated lists of prescription drugs, organized into cost-sharing tiers. When the FDA reclassified minoxidil topical as an OTC product, insurers lost the legal requirement to include it in formulary negotiations. Security Health Plan, administered through Marshfield Clinic Health System in Wisconsin, follows this standard practice. Their published formulary documents list covered prescription medications, and OTC products like Rogaine do not appear unless the plan includes a specific OTC benefit rider.

Some employer-sponsored Security Health Plan contracts do include limited OTC allowances. These allowances typically cover items like allergy medications, pain relievers, or smoking cessation aids rather than cosmetic or hair-regrowth products. A 2023 Kaiser Family Foundation survey found that only 14% of employer plans offered any OTC drug benefit, and hair loss products were among the least frequently included categories [1].

This does not mean all minoxidil formulations are unreachable through insurance. The prescription oral tablet form exists, and that distinction matters.

Prescription Oral Minoxidil: A Potentially Covered Alternative

Oral minoxidil tablets (typically dosed at 0.625 mg to 5 mg daily for hair loss) remain prescription-only, which places them within the scope of pharmacy benefit coverage. A growing body of evidence supports low-dose oral minoxidil for androgenetic alopecia, and some Security Health Plan members have successfully obtained coverage for this formulation.

Dr. Rodney Sinclair, a dermatology professor at the University of Melbourne who has published extensively on oral minoxidil, stated: "Low-dose oral minoxidil represents a genuine therapeutic advance for patients who cannot tolerate or apply topical formulations consistently" [2]. His research group published a dose-finding study in the Journal of the American Academy of Dermatology showing that oral minoxidil at 5 mg daily produced hair density increases of 12.7 hairs per cm² over 24 weeks in women with female pattern hair loss (N=30) [2].

A larger retrospective study published in 2022 reviewed 1,404 patients treated with low-dose oral minoxidil across multiple dermatology centers. The results, reported in the Journal of the American Academy of Dermatology, showed that 65% of patients experienced clinically meaningful improvement at 6 months, with adverse effects (primarily hypertrichosis) occurring in 15.1% of cases [3].

To pursue coverage through Security Health Plan, you will need a prescriber to write the prescription and submit it to the plan pharmacy. If the initial claim is denied, the prescriber can file a prior authorization with clinical documentation of diagnosis and treatment rationale.

How to Check Your Specific Security Health Plan Benefits

Your coverage depends on your exact plan type, employer contract, and formulary year. Security Health Plan operates several distinct products, and each maintains its own drug list.

Call the member services number printed on the back of your Security Health Plan ID card. Ask specifically: "Is oral minoxidil covered under my pharmacy benefit, and does it require prior authorization?" The representative can run a real-time formulary check using your member ID. You can also search the Security Health Plan formulary online through their member portal.

For Medicare Advantage members, the rules differ. Security Health Plan offers Medicare plans in central and northern Wisconsin, and these plans follow CMS formulary guidelines. Medicare Part D plans are required to cover at least two drugs per therapeutic class, but "hair growth agents" is not a mandatory class. The American Academy of Dermatology notes that Medicare coverage for hair loss medications remains inconsistent across plan sponsors [4].

If your pharmacist runs the claim and receives a rejection, ask for the specific rejection code. Common codes include "product not covered" (meaning formulary exclusion) and "prior authorization required" (meaning the plan may cover it with additional documentation). These are different situations that require different responses.

The Real Cost of Rogaine Without Insurance

Paying out of pocket for Rogaine or generic minoxidil is often more affordable than patients expect. This cost analysis matters because even if your Security Health Plan does cover a prescription alternative, the copay may exceed the retail price of the OTC product.

Brand-name Rogaine 5% foam (men's formulation) retails for $30 to $55 for a one-month supply at major pharmacy chains. The women's 2% solution costs slightly less, typically $25 to $45 per month. Generic topical minoxidil, available from multiple manufacturers, drops the price to $10 to $20 per month at retailers like Walmart, Costco, and Amazon.

A cost-effectiveness analysis published in JAMA Dermatology compared hair loss treatments over a 5-year horizon. Topical minoxidil 5% cost approximately $240 to $660 per year, while oral finasteride (generic) cost $48 to $120 per year with a prescription [5]. The analysis concluded that generic oral finasteride offered the lowest cost per quality-adjusted life year among all FDA-approved hair loss treatments.

Oral minoxidil tablets, when prescribed, cost $4 to $15 per month at pharmacies offering generic pricing programs. If Security Health Plan covers the prescription with a Tier 1 copay ($5 to $15 typical), the out-of-pocket difference between the covered prescription and the OTC product becomes minimal.

Finasteride and Dutasteride: Hair Loss Drugs More Likely to Be Covered

Security Health Plan formularies are more likely to include oral finasteride (generic Propecia) and potentially dutasteride (generic Avodart) than any minoxidil product. Both are prescription-only 5-alpha reductase inhibitors, and both carry FDA approvals that keep them within standard formulary structures.

Finasteride 1 mg daily is FDA-approved specifically for male androgenetic alopecia. The key trials demonstrated that finasteride 1 mg increased hair count by a mean of 107 hairs per 1-inch circle of scalp at 2 years, compared to a loss of 101 hairs in the placebo group (N=1,553) [6]. That is a net difference of 208 hairs in the measured area. Security Health Plan typically lists generic finasteride on Tier 1 or Tier 2, making it the most insurance-friendly hair loss medication.

Dutasteride 0.5 mg, approved for benign prostatic hyperplasia but prescribed off-label for hair loss, showed superior efficacy to finasteride in a head-to-head randomized trial published in the Journal of the American Academy of Dermatology. At 24 weeks, dutasteride 0.5 mg increased target area hair count by 12.2 hairs per cm² versus 4.7 hairs per cm² for finasteride 1 mg (N=917) [7]. Coverage for dutasteride as a hair loss treatment may require prior authorization since the off-label indication is not the approved use.

The Endocrine Society clinical practice guidelines recommend that clinicians discuss both 5-alpha reductase inhibitors and topical minoxidil as first-line options for androgen-dependent hair loss, noting: "Combination therapy with finasteride and minoxidil may provide additive benefit over monotherapy with either agent alone" [8].

Filing an Appeal if Coverage Is Denied

Insurance denials for hair loss medications are common, but they are not final. Security Health Plan, like all Wisconsin-regulated health insurers, must provide a formal appeals process governed by Wisconsin OCI regulations.

Start with an internal appeal. Your prescribing physician should write a letter of medical necessity documenting the diagnosis (ICD-10 code L64.9 for alopecia, unspecified, or L65.9 for nonscarring hair loss), treatment history, and clinical rationale for the requested medication. Include photographs showing the extent of hair loss and any validated severity scores such as the Hamilton-Norwood scale for men or the Ludwig scale for women.

If the internal appeal is denied, you can request an external review through the Wisconsin Office of the Commissioner of Insurance. External reviews are conducted by independent physicians who are not affiliated with Security Health Plan. The external reviewer's decision is binding on the insurer.

A study published in the American Journal of Managed Care found that 45% of prescription drug denials were reversed on first-level internal appeal when accompanied by physician documentation (N=1.2 million appeals reviewed across commercial plans) [9]. The reversal rate dropped to 22% at external review, but the combined probability of eventually obtaining coverage through the full appeals process exceeded 55% for drugs with published clinical evidence supporting the indication.

Document every interaction. Record the date, representative name, reference number, and outcome of each call to Security Health Plan member services.

Compounding Pharmacies and Combination Products

Some dermatologists prescribe compounded minoxidil formulations that combine minoxidil with finasteride, tretinoin, or other active ingredients in a single topical solution. These compounded products are prescription-only by definition, which places them within the technical scope of pharmacy benefits.

Security Health Plan's coverage of compounded medications varies by plan. Many commercial insurers exclude compounded drugs from standard formularies or require them to be processed through a specialty pharmacy. The FDA has stated that compounded medications are not FDA-approved and do not undergo the same safety and efficacy review as commercially manufactured products [10].

A compounded topical solution containing minoxidil 5% plus finasteride 0.1% costs $50 to $120 per month at most compounding pharmacies. If your Security Health Plan does not cover the compound, the out-of-pocket cost may still be reasonable when compared to purchasing the two active ingredients separately. A pilot study in the British Journal of Dermatology (N=50) found that topical finasteride 0.25% combined with minoxidil 3% produced a 16.2% increase in total hair count at 24 weeks versus 11.8% for minoxidil alone [11].

What Security Health Plan Members Should Do Next

If you have Security Health Plan and want treatment for hair loss, a clear action sequence will save time and money.

First, see a board-certified dermatologist for a formal diagnosis. Hair loss has dozens of causes, and treatment depends on the underlying condition. Telogen effluvium, alopecia areata, and androgenetic alopecia each require different approaches. Insurance is more likely to cover treatment when the medical record documents a specific diagnosis and failed conservative measures.

Second, ask your dermatologist about prescription options. Generic oral finasteride (for men) and oral minoxidil (for either sex) are both prescription drugs that can be submitted to Security Health Plan pharmacy benefits. Your dermatologist can check real-time formulary status at the point of prescribing using electronic prior authorization tools integrated into most EHR systems.

Third, if you prefer topical minoxidil specifically, purchase the generic OTC version. At $10 to $20 per month, generic topical minoxidil 5% is among the most affordable treatments in all of dermatology. The Cochrane Collaboration systematic review of topical minoxidil for female pattern hair loss (12 trials, 1,006 participants) confirmed that minoxidil 5% was superior to placebo for total hair count and investigator-assessed regrowth, with mild local irritation as the most common side effect [12].

Apply minoxidil 5% solution or foam to the affected scalp area once daily (for 5% formulation) or twice daily (for 2% formulation). Results require 4 to 6 months of consistent use before visible changes appear. Discontinuation leads to gradual loss of regained hair over 3 to 6 months.